Foot orthoses and corticosteroid injection are common interventions used for plantar heel pain, however few studies have investigated the variables that predict response to these interventions.
Methods
Baseline variables (age, weight, height, body mass index (BMI), sex, education, foot pain, foot function, fear-avoidance beliefs and feelings, foot posture, weightbearing ankle dorsiflexion, plantar fascia thickness, and treatment preference) from a randomised trial in which participants received either foot orthoses or corticosteroid injection were used to predict change in the Foot Health Status Questionnaire foot pain and foot function subscales, and first-step pain measured using a visual analogue scale. Multivariable linear regression models were generated for different dependent variables (i.e. foot pain, foot function and first-step pain), for each intervention (i.e. foot orthoses and corticosteroid injection), and at different timepoints (i.e. weeks 4 and 12).
Results
For foot orthoses at week 4, greater ankle dorsiflexion with the knee extended predicted reduction in foot pain (adjusted R2 = 0.16, p = 0.034), and lower fear-avoidance beliefs and feelings predicted improvement in foot function (adjusted R2 = 0.43, p = 0.001). At week 12, lower BMI predicted reduction in foot pain (adjusted R2 = 0.33, p < 0.001), improvement in foot function (adjusted R2 = 0.37, p < 0.001) and reduction in first-step pain (adjusted R2 0.19, p = 0.011). For corticosteroid injection at week 4, there were no significant predictors for change in foot pain or foot function. At week 12, less weightbearing hours predicted reduction in foot pain (adjusted R2 = 0.25, p = 0.004) and lower baseline foot pain predicted improvement in foot function (adjusted R2 = 0.38, p < 0.001).
Conclusions
People with plantar heel pain who use foot orthoses experience reduced foot pain if they have greater ankle dorsiflexion and lower BMI, while they experience improved foot function if they have lower fear-avoidance beliefs and lower BMI. People who receive a corticosteroid injection experience reduced foot pain if they weightbear for fewer hours, while they experience improved foot function if they have less baseline foot pain.
Opmerkingen
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Afkortingen
VAS
Visual analogue scale
BMI
Body mass index
FHSQ
Foot Health Status Questionnaire
FACS
Fear-Avoidance Components Scale
Background
Plantar heel pain is a disabling foot condition that has a significant impact on health-related quality of life [1]. Prevalence estimates of plantar heel pain in the community range between 4 and 10% [2‐4], while in athletes, prevalence estimates range between 5 and 18% [5]. Despite the relatively high prevalence of plantar heel pain, there is limited high-quality evidence to guide health professionals regarding the interventions that are most effective.
A recent randomised trial (the SOOTHE heel pain trial) aimed to clarify the effectiveness of two common interventions used to treat plantar heel pain, which were foot orthoses and corticosteroid injection [6]. The trial found that corticosteroid injection was more effective than foot orthoses in the short term (at week 4) and that foot orthoses were more effective than corticosteroid injection in the longer term (at week 12). The published article that presented the findings for this trial focused on the comparative effectiveness of these interventions, but it did not provide information about the variables that predict response to each intervention [6]. Understanding variables that predict response may help health professionals choose interventions that are most appropriate for their patients and assist researchers to design clinically relevant randomised trials.
To our knowledge, there is only one study that has evaluated variables that predict pain or function for foot orthoses and corticosteroid injection for plantar heel pain [7]. The authors evaluated variables to predict response to a combination of foot orthoses, calf stretches, new footwear, and ice massage for people with plantar heel pain. This study, which was a secondary analysis of a randomised trial, found that heel valgus in stance, and first-step pain greater than 7/10 on a visual analogue scale (VAS) were predictive of a worse response, while an inability to dorsiflex the ankle past 5 degrees with the knee extended using a non-weightbearing assessment was predictive of an improved response. There are no studies that have evaluated variables that predict change in pain or function for corticosteroid injection.
Given the available evidence, the aim of this study was to investigate which factors influence the response to foot orthoses and corticosteroid injection in people with plantar heel pain. Baseline variables (age, weight, height, body mass index (BMI), sex, education, foot pain, foot function, fear-avoidance beliefs and feelings, foot posture, ankle dorsiflexion, plantar fascia thickness, and treatment preference) were used to predict the change in foot pain, foot function, and first-step pain after 4 and 12 weeks.
Methods
Data for this study were obtained from a published, assessor-blinded, randomised trial that evaluated the comparative effectiveness of foot orthoses and corticosteroid injection for plantar heel pain [6]. Detailed methods of the trial are available from the published protocol [8]. Participants were randomly allocated to receive either foot orthoses or a single ultrasound-guided corticosteroid injection and were followed up for 12 weeks. The trial was prospectively registered with the Australian New Zealand Clinical Trials Registry (registration ACTRN12615001266550). Ethical approval was obtained from the La Trobe University Human Ethics Committee (approval number 15–120) and all participants provided informed consent.
Participants
Participants were included in the trial if they were over 18 years of age, had a diagnosis of plantar heel pain of at least 4 weeks duration [8, 9], and reported an average pain over the last 7 days of at least 30 mm on a 100 mm VAS. Participants were excluded if they had received any treatment in the past 4 weeks, had worn foot orthoses or received a corticosteroid injection in the heel in the last 6 months, had a history of surgery to the heel, or had a systemic medical condition such as an inflammatory disorder, connective tissue disease, or neurological disorder.
Interventions
Participants randomised to the foot orthoses group received a pair of Formthotics™ prefabricated foot orthoses (Foot Science International, Christchurch, New Zealand). The Formthotics™ were full-length, dual-density devices manufactured from a soft polyethylene foam top layer (Shore A durometer 25) and a firm polyethylene foam base layer (Shore A durometer 50) (Fig. 1). The foot orthoses were fitted for each participant by a podiatrist who selected the appropriate size and heated the foot orthoses in the shoes with a device specifically designed for this purpose by Foot Science International. Each participant stood with the foot orthoses in their shoes to allow them to mould appropriately. Modifications were not made unless the participant experienced discomfort.
Fig. 1
Formthotics full-length, dual-density, prefabricated foot orthosis. a View of the lateral orthosis, (b) view of the medial orthosis, and (c) view from the distal to the proximal end of the orthosis [8]
×
Participants randomised to the corticosteroid injection group received a single ultrasound-guided corticosteroid injection from a radiologist. Participants were placed in a prone position, with their feet hanging from the end of an examination table (Fig. 2). A 25 gauge needle was used to inject a solution containing 1 mL of a combination of betamethasone acetate and betamethasone sodium phosphate (Celestone® Chronodose®), and 1 mL of bupivacaine (Marcaine® 0.5%).
Fig. 2
Technique used to administer the ultrasound-guided corticosteroid injection [8]
×
Participants in both groups received education about plantar heel pain, and were advised to carry out plantar fascia and calf stretches [8].
Outcome measures
Outcome measures were obtained at baseline, week 4, week 8, and week 12. Several outcome measures were used for the randomised trial; the following outcome measures are those that are relevant to this study.
(i)
Participant characteristics: including age, sex, BMI, foot posture [10], education, self-reported weightbearing hours, and weightbearing ankle dorsiflexion [11]. Participants were also asked their treatment preference and duration of symptoms.
(ii)
Foot pain: measured using the Foot Health Status Questionnaire (FHSQ) pain subscale (primary outcome) [12], and a VAS to measure the severity of ‘first step’ and average pain.
(iii)
Foot function: measured using the FHSQ foot function subscale [12].
(iv)
Self-reported physical activity: measured using the 7-day Physical Activity Recall Questionnaire [13]. The results were converted to daily energy expenditure expressed in kcal/day [14].
(v)
Fear-avoidance beliefs and feelings: measured using the Fear-Avoidance Components Scale (FACS) [15].
(vi)
Plantar fascia thickness and hypoechogenicity: measured sonographically (at weeks 4 and 12) using a Siemens Acuson Antares (Siemens Healthcare GmbH, Erlangen, Germany) with a linear 5–12 MHz probe.
Statistical analysis
Statistical analyses were performed using Stata version 16.0 (StataCorp LLC, Texas, United States of America). Standard tests of the distribution of continuous data were undertaken, and any variables with skewed data were transformed if appropriate. The normality of residuals was inspected with Kernel plots, P-P plots and Q-Q plots. Homoscedasticity was evaluated by plotting residuals versus predicted values and using the imtest and hettest commands in Stata. Multicollinearity was controlled by visually inspecting pairwise correlations and by ensuring the variation inflation factor was less than 10 for each predictor. Linearity was evaluated by plotting the standardised residuals against each of the predictor variables in the regression model using scatterplots and augmented partial residual plots [16]. Missing data were replaced using multiple imputation [17]. Little’s test was used to ensure data were missing completely at random (MCAR), and to determine the subsequent method for generating the imputed datasets [18]. Regression models were created using age, sex, BMI, and baseline values as predictors. The estimates from 30 imputed datasets were combined using Rubin’s rules [19]. We chose to use 30 imputed datasets to reduce sampling variability from the imputation process [17].
To identify predictor variables for inclusion in multivariable linear regression models, Pearson’s pairwise correlation coefficients were calculated between potential predictor variables and the dependent variables (the FHSQ foot pain subscale, the FHSQ foot function subscale, and first-step pain measured with a VAS). Significant pairwise correlation coefficients (p < 0.10) were entered in multiple linear regression models using forward hierarchical selection. Due to the sample size, only the strongest four predictor variables (determined by the magnitude of Pearson’s r) were entered into the model to prevent overfitting [20]. In order to predict response, baseline scores of the predictor variable were included in the model, as well as covariates age, sex and BMI. Separate regression models were developed for each intervention (i.e. foot orthoses and corticosteroid injection), dependent variable (i.e. foot pain, foot function and first-step pain), and at two timepoints (i.e. at weeks 4 and 12). Regression models were generated in Stata version 16.0 using the mibeta command, and the means of the imputed R2 estimates were transformed using Fisher’s r to z transformation (fisherz command) to provide a better estimate [21]. Significance for the multivariable regression models was α = 0.05.
Results
A total of 220 people were screened for eligibility between May 2016 and June 2017, and 103 participants were randomised and received a treatment. Participant characteristics are outlined in Table 1. Data were missing for 6% (n = 7 participants) of the data at week 4, and 2% (n = 2 participants) of the data at week 12. The data were deemed to be missing completely at random (Little’s MCAR test: Chi-Square = 276.43, degrees of freedom 762, p-value > 1.00). The missing values were replaced using the predictive mean matching method of multiple imputation in Stata version 16.0.
Table 1
Participant characteristics and relevant baseline outcome measures
Characteristic
Foot orthoses (n = 53)
Corticosteroid injection (n = 50)
Age, years
42.9 (10.9)
44.9 (12.8)
Number of women, n (%)
33 (62.3)
30 (60.0)
Weight, kg
88.1 (21.5)
86.9 (21.7)
Height, m
1.7 (0.9)
1.7 (1.0)
Body mass index, kg/m2
31.1 (6.6)
29.7 (5.9)
Education, years
15.5 (2.7)
15.1 (3.6)
Duration of symptoms, months (median and interquartile range)
6 (8)
6 (8)
Weightbearing hours
6.9 (3.3)
7.2 (3.5)
Allocated to preferred treatment, n (%)
21 (39.6)
21 (42.0)
Plantar fascia thickness, mma
5.9 (1.1)
5.8 (1.5)
Foot Posture Indexb
3.6 (3.3)
3.7 (3.7)
Ankle dorsiflexion, degrees
Knee extended
40.2 (6.9)
37.9 (6.9)
Knee flexed
45.9 (8.3)
44.7 (7.3)
Baseline outcome measures
FHSQ pain subscalec
38.4 (17.3)
38.5 (17.0)
FHSQ footwear subscalec
43.1 (21.1)
50.3 (21.1)
Baseline pain (measured using a VAS)d
51.1 (16.7)
56.8 (17.9)
First-step pain (measured using a VAS)d
68.2 (14.9)
72.5 (16.4)
FACSe
30.8 (18.0)
29.6 (16.6)
Abbreviations: FHSQ Foot Health Status Questionnaire, FACS Fear-Avoidance Components Scale, VAS visual analogue scale
aBased on the most painful foot
bScores range from − 12 (highly supinated foot) to + 12 (highly pronated foot). A score between 1 and 7 indicates a normal foot posture [22]
cScores on the FHSQ range from 0 (most pain/difficulty with footwear) to 100 (no pain/no difficulty with footwear)
dScores on the VAS range from 0 (no pain) to 100 (worst pain imaginable)
eScores on the FACS range from 0 (no fear-avoidance beliefs) to 100 (extreme fear-avoidance beliefs)
Univariable analyses
For foot orthoses, predictor variables that were significantly correlated (p < 0.10) with the dependent variables at weeks 4 and 12 are summarised in Table 2. For corticosteroid injection, predictor variables that were significantly correlated with the dependent variables at weeks 4 and 12 are summarised in Table 3. There were no significant predictors identified for foot pain and first step-pain at week 4.
Table 2
Significant predictor variables based on univariable analyses for foot orthoses at weeks 4 and 12
Dependent variable
Predictor variable
Pearson’s r
P-valuea
Week 4
Foot pain
Ankle dorsiflexion – knee extended
0.36
0.013
Foot Posture Index
−0.35
0.015
Foot function
FACS
−0.63
0.001
FHSQ footwear subscale
0.37
0.010
First-step pain
Ankle dorsiflexion – knee extended
−0.39
0.006
Preference for foot orthoses
0.28
0.059
Week 12
Foot pain
BMI
−0.43
0.001
Duration of symptoms
−0.28
0.047
Foot function
BMI
−0.46
0.000
FACS
−0.38
0.005
FHSQ footwear subscale
−0.36
0.009
First-step pain
−0.25
0.077
First-step pain
BMI
0.43
0.002
Weightbearing hours
0.29
0.031
Age
−0.29
0.036
Abbreviations: FACS Fear-Avoidance Components Scale, FHSQ Foot Health Status Questionnaire, BMI body mass index
aThe alpha level to include predictors was 0.10
Table 3
Significant predictors based on univariable analyses for corticosteroid injection at weeks 4 and 12
Dependent variable
Predictor variable
Pearson’s r
P-valuea
Week 4b
Foot function
FHSQ footwear subscale
−0.45
0.001
Baseline pain (measured using a VAS)
−0.32
0.021
FACS
−0.31
0.031
Week 12
Foot pain
Weightbearing hours
−0.33
0.020
Foot function
FACS
−0.42
0.002
Baseline pain (measured using a VAS)
−0.39
0.005
FHSQ footwear subscale
−0.29
0.043
First-step pain
−0.24
0.094
First-step pain
Weightbearing hours
0.34
0.017
Abbreviations: FHSQ Foot Health Status Questionnaire, FACS Fear-Avoidance Components Scale, VAS visual analogue scale
aThe alpha level to include predictors was 0.10
bThere were no significant predictors at week 4 for foot pain and first-step pain
Multivariable linear regression analyses
Foot orthoses
Table 4 displays the results of the multivariable linear regression analyses for the dependant variables foot pain, foot function, and first-step pain at weeks 4 and 12. For foot pain at week 4, a model that included ankle dorsiflexion with the knee extended explained 16% of the variance in the FHSQ foot pain subscale (F5, 44.3 = 2.66, p = 0.034). Univariable analysis found that the Foot Posture Index was a significant predictor, however it was not significant in the multivariable model. This model suggests that greater ankle dorsiflexion predicted reduction in foot pain at week 4. For foot function at week 4, a model that included the FACS explained 43% of the variance in the FHSQ foot function subscale (F5, 43.2 = 6.89, p = 0.001). Univariable analysis found the FHSQ footwear subscale was a significant predictor, however it was not significant in the multivariable model. This model suggests that lower fear-avoidance predicted improvement in foot function at week 4. For first-step pain at week 4, a model that included ankle dorsiflexion with the knee extended explained 15% of the variance using a VAS, however it was not statistically significant (F5, 43.8 = 2.26, p = 0.064). Univariable analysis found participant preference to receive foot orthoses was a significant predictor, however it was not significant in the multivariable model.
Table 4
Multivariable linear regression models for foot orthoses at weeks 4 and 12
Dependent variable
Unstandardised coefficients
Standardised coefficients
Modela
β
SE β
β
t-value
P-valueb
R2
Adjusted R2
Week 4
Foot pain
Ankle dorsiflexion – knee extended
0.813
0.377
0.309
2.15
0.037
0.25
0.16*
Foot function
FACS
−0.271
0.132
−0.318
−2.06
0.047
0.49
0.43*
First-step pain
Ankle dorsiflexion – knee extended
−1.327
0.529
−0.353
−2.51
0.016
0.24
0.15
Week 12
Foot pain
BMI
−1.237
0.424
−0.389
−2.92
0.006
0.39
0.33*
Duration of symptoms
−0.364
0.175
−0.251
−2.08
0.044
Foot function
BMI
−0.671
0.288
−0.298
−2.33
0.025
0.42
0.37*
First-step pain
BMI
1.220
0.430
0.406
2.83
0.007
0.25
0.19*
Age
−0.503
0.228
−0.276
−2.20
0.033
Abbreviations: SE standard error, FACS Fear-Avoidance Components Scale, BMI body mass index
aAdjusted for age, sex, BMI, and baseline scores of the dependent variable
bThe p-value represents the statistical significance of individual variables
* The p-value of the adjusted R2 was < 0.05
For foot pain at week 12, a model that included BMI and duration of symptoms explained 33% of the variance in the FHSQ foot pain subscale (F5, 44.6 = 5.56, p < 0.001). This model suggests that lower BMI and a shorter duration of symptoms predicted reduction in foot pain at week 12. For foot function at week 12, BMI explained 37% of the variance in the FHSQ foot function subscale (F4, 45.3 = 7.68, p < 0.001). Univariable analysis found fear avoidance, the FHSQ footwear subscale, and first-step pain were significant predictors, however they were not significant in the multivariable model. This model suggests that lower BMI predicted improvement in foot function at week 12. For first-step pain at week 12, a model containing age and BMI explained 19% of the variance in a VAS (F4, 45.5 = 3.68, p = 0.011). This model suggests that lower BMI and older age predicted reduction in first-step pain at week 12. Univariable analysis found weightbearing hours was a significant predictor, however it was not significant in the multivariable model.
Corticosteroid injection
Table 5 displays the results of the multivariable linear regression analyses at week 12 (there were no significant predictors in the multivariable models at week 4). For foot pain at week 12, a model that included weightbearing hours explained 25% of the variance in FHSQ foot pain (F5, 42 = 4.10, p = 0.004). This model suggests that less weightbearing hours predicted reduction in foot pain at week 12. For foot function at week 12, a model that included baseline pain measured using a VAS explained 38% of the variance in the FHSQ foot function subscale (F5, 41.8 = 6.52, p < 0.001). This model suggests that lower baseline foot pain predicted improvement in foot function at week 12. Univariable analysis found that the FACS, the FHSQ footwear subscale and first-step pain were significant predictors, however they were not significant in the multivariable model. For first-step pain at week 12, a model that included weightbearing hours explained 10% of the variance in a VAS (F5, 42.0 = 1.99, p = 0.100), however it was not statistically significant.
Table 5
Multivariable linear regression models for corticosteroid injection at weeks 4 and 12
Unstandardised coefficients
Standardised coefficients
Dependent variablea
Modelb
β
SE β
β
t-value
P-valuec
R2
Adjusted R2
Week 12
Foot pain
Weightbearing hours
−1.742
1.011
−0.235
−1.72
0.092
0.32
0.25*
Foot function
Baseline pain (measured using a VAS)
−0.323
0.156
−0.285
−2.07
0.046
0.44
0.38*
First-step pain
Weightbearing hours
2.482
1.339
0.284
7.85
0.071
0.19
0.10
Abbreviations: SE standard error, BMI body mass index, VAS visual analogue scale
aThere were no significant predictors at week 4
bAdjusted for age, sex, BMI, and baseline scores of the dependent variable
cThe p-value represents the statistical significance of individual variables
* The p-value of the adjusted R2 was < 0.05
Discussion
This aim of this study was to identify variables from a recent randomised trial that predict response to foot orthoses and corticosteroid injection in people with plantar heel pain [6]. For each intervention, we evaluated whether baseline variables (age, weight, height, BMI, sex, education, foot pain, foot function, fear-avoidance beliefs and feelings, foot posture, ankle dorsiflexion, plantar fascia thickness, and treatment preference) could be used to predict change of foot pain, foot function, and first-step pain. We found that predictors differed for each intervention, dependent variable, and at each timepoint (i.e. at 4 weeks and 12 weeks).
Foot orthoses
At week 4, greater ankle dorsiflexion predicted reduction in foot pain for people who received foot orthoses. Previous studies have found that reduced ankle dorsiflexion is associated with plantar heel pain [23‐27], while other studies have found that greater ankle dorsiflexion is associated with plantar heel pain [28, 29]. One past study that evaluated predictors of response to foot orthoses found that participants with markedly reduced ankle dorsiflexion had a better response [7]. However, the statistical analysis used in this study is quite different to our study, which makes a direct comparison difficult. Further research will be required to understand whether ankle dorsiflexion can be used to predict response for people who receive foot orthoses for plantar heel pain.
Univariable analyses found that the FACS was associated with foot function for both interventions and at both timepoints. This finding is supported by a past study that found a similar pain-related fear construct, fear of movement/(re) injury, was associated with worse foot function in people with plantar heel pain [30]. However, using multivariable analysis in our study, lower fear-avoidance was a predictor of improvement in foot function for the foot orthoses group at week 4 only; explaining 43% of the variance in the FHSQ foot function subscale. These findings suggest that fear-avoidance beliefs may be associated with worse foot function, however they only predict worse foot function in the short term with the use of foot orthoses. The significance of these findings is uncertain, however they may help to explain why some patients do not respond to foot orthoses in the short term. Indeed, past research has found that fear-avoidance related symptoms negatively affect treatment outcomes for patients with chronic musculoskeletal pain [31‐33]. Therefore, patients with elevated fear-avoidance beliefs and feelings may benefit from additional interventions to address these beliefs.
At week 12, lower BMI was a consistent predictor of a favourable response to foot orthoses. Lower BMI predicted reduction in foot pain (in conjunction with shorter duration of symptoms), improvement in foot function, and reduction in first-step pain (in conjunction with younger age). A past meta-analysis identified BMI as one of the most important factors associated with plantar heel pain, although this finding differs between athletic and non-athletic populations [34].
Corticosteroid injection
At week 4, there were no significant predictors for foot pain (including first-step pain) and the significant predictors for foot function identified by univariable analyses were not significant in multivariable models. Difficulty identifying predictors of response following corticosteroid injection is not unique to plantar heel pain, and has also been reported for other conditions such as knee [35] and hip osteoarthritis [36], and idiopathic trigger finger [37]. For plantar heel pain, this is the first study to predict change in pain or function following a corticosteroid injection, with the only previous study predicting change in tenderness thresholds [38].
At week 12, less baseline weightbearing hours predicted reduction in foot pain and lower baseline foot pain (i.e. foot pain severity measured using a VAS) predicted improvement in foot function. A previous meta-analysis that included four studies found that more weightbearing hours was associated with plantar heel pain [34]. Our study is the first to identify that this variable can predict response in those with plantar heel pain, although it is unclear why this variable was only a predictor for corticosteroid injection. Foot orthoses can modify plantar pressures at the heel [39‐42], which may explain why weightbearing hours was only a predictor for corticosteroid injection.
For foot function, lower baseline pain predicted improvement in foot function and explained 38% of the variance in this model. There have been contrasting findings from past studies regarding the association of foot pain on function. One study that evaluated the relationship between pain intensity and function in those with plantar heel pain found no association [43]. However, research with older adults from the community has found that foot pain is associated with functional impairment [44, 45]. Our study suggests that baseline foot pain is important for predicting improvement in foot function, however this finding is only apparent following corticosteroid injection.
Limitations
The findings of this study should be interpreted with respect to some limitations. First, the data for this study is a secondary analysis of a randomised trial that evaluated foot orthoses and corticosteroid injection for plantar heel pain. Therefore, the data obtained from participants relates to the aim of the randomised trial rather than the aim of this study, which may have influenced the data collected. Second, the sample size was determined to power the randomised trial rather than this study, which limited the number of predictors that could be included in the multivariable regression models. Third, the results of this study are specific to the interventions used in the randomised trial. It is possible that we could have obtained different findings if a different type of orthosis or corticosteroid injection was used. Finally, the overall variance explained by the models is modest and there may be important predictors that were not included as outcome measures in the randomised trial. Therefore, important predictors of response may not have been measured, such as comorbidities or certain imaging features.
Future research
There are no studies that have performed an a priori evaluation of the predictors of response to treatment of plantar heel pain. An a priori evaluation can overcome many of the limitations discussed above and generate more robust findings. Understanding variables that predict response is important because it can help health professionals choose more appropriate interventions for their patients and can assist with the design of clinically relevant randomised trials. For example, the findings of this study may inform randomised trials of foot orthoses that may stratify by predictors, such as ankle dorsiflexion. Another area for future research is that we found no predictors of response for participants who received a corticosteroid injection in the short term. Change in pain is important for patients with plantar heel pain and future research is needed to identify important predictors to improve outcome for corticosteroid injection [46].
Conclusions
For individuals with plantar heel pain, the predictors of response differed for foot orthoses and corticosteroid injection. For foot orthoses, we found that greater ankle dorsiflexion and lower BMI predicted reduction in foot pain, while lower fear-avoidance beliefs and feelings, as well as lower BMI predicted improvement in foot function. For corticosteroid injection, we found that less weightbearing hours predicted reduction in foot pain, and lower baseline foot pain predicted improvement in foot function. These findings may be used to inform the design of future research.
Acknowledgements
HBM is currently a National Health and Medical Research Council Senior Research Fellow (ID: 1135995).
Ethics approval and consent to participate
Ethical approval was obtained from the La Trobe University Human Ethics Committee (approval number 15–120), and all participants provided informed consent.
Consent for publication
Not applicable
Competing interests
The authors report no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.
